Benign Prostatic Hyperplasia
Conditions
Keywords
Benign Prostate Hyperplasia, IPSS (International Prostate Symptom Score), LUTS (Lower Urinary Tract Symptoms)
Brief summary
Investigation of the efficacy and safety of the stable combination of dutasteride and tamsulosin (Dinaplex®) in the Greek population as well as the evaluation of the quality of life of patients with benign prostatic hyperplasia (BPH) in treatment with a stable combination of dutasteride and tamsulosin (Dinaplex®)
Detailed description
Combination therapy with the 5-α reductase inhibitor, dutasteride, and the α-blocker, tamsulosin, in men with moderate to severe benign prostatic hyperplasia and prostate enlargement, was studied in the Combination of Avodart ™ and Tamsulosin (CombAT) which was a four-year, global, multicenter, randomized, double-blind, parallel design (3 arms) study. The aim of the study was to investigate the benefits of combination therapy (dutasteride-tamsulosin) compared to monotherapy in terms of improvement of symptoms and long-term results (AUR and surgery), in men with moderate to severe BPH. The primary endpoint in the two years since the start of the study was the change in the IPSS score, while the primary endpoint, after four years of treatment, was the time until the long-term results manifested (i.e. AUR or CF surgery) as well as the percentage of participants who were led to them. Patients were at least 50 years old with a prostate tumor ≥30 cm3 and a PSA level ≥ 1.5 ng / mL. 4838 men (39) participated in this study.
Interventions
OTHERPatients with Benign Prostate Hyperplasia
patients with benign prostatic hyperplasia under fixed dose combΙnation treatment with dutasteride and tamsulosin
Sponsors
Elpen Pharmaceutical Co. Inc.
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 85 Years
Inclusion criteria
* Adult male patient with moderate to severe BPH symptoms receiving either monotherapy, dual medication as monoproducts or other stable combination and not responding adequately to treatment. * Adult male patient with BPH who has fully understood the study procedures and has signed a consent form after information.
Exclusion criteria
* Patient who does not meet the criteria for taking the study drug (s), according to the Summary of Product Characteristics of each drug in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of disease control (BPH), PROSPERITY I Evaluation of quality of life. PROSPERITY II | 3-6 months | The change in the overall score (questions 1-7) of the IPSS (International Prostate Symptom Score) questionnaire. PROSPERITY I. The change in the score of the question related to quality of life, of the IPSS questionnaire. PROSPERITY II |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of disease control (BPH), PROSPERITY II. | 3-6 months | The change in the overall score (questions 1-7) of the IPSS (International Prostate Symptom Score) questionnaire. PROSPERITY II. |
| U/S measurement. PROSPERITY I&II | 3-6 months | The change in the volume of the prostate and the change in the volume of the remaining urine (measurement by ultrasound). |
| Number of AEs (PROSPERITY I&II) | 3-6 months | The recording of Adverse Events (Adverse Events, SA) if they occur during the study. |
Countries
Greece
Outcome results
None listed